ImageneBio, Inc. (IMA) stock
Close on Nov 11, 2026Market cap $42.23MP/E –Yield –
ImageneBio, Inc. saw revenue fall 77.1% to $800.00K over fiscal 2025. At the latest close the market valued the company at $42.23M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $42.23M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.33
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $800.00K
- Net income
- -$43.33M
- EPS, diluted
- -$9.64
- Book value per share
- $7.48
- Diluted shares
- 17M
Trading
- Next earnings
- Mar 9, 2027 (estimated, before the open)
- Previous close
- $3.81
- Open
- $3.81
- Day's range
- $3.71 – $3.85
- Volume
- 3,938
- Average volume (20 days)
- 11,595
- Beta (5 years)
- 1.17
- 52-week range
- $3.60 – $8.84
- RSI (14 days)
- 30.6
- Volatility (1 year)
- 56.9%
- Relative volume
- 0.31×
- WACC
- 10.7%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | IMA | S&P 500 | Difference | IMA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -12.3% | -2.4% | −9.9 pts | ||
| 3 months | -33.7% | -1.2% | −32.5 pts | ||
| Year to date | -46.1% | +12.3% | −58.4 pts | ||
| 1 year | -56.8% | +12.4% | −69.2 pts | ||
| 3 years | -78.8% | +78.8% | −157.6 pts | -40.3% | +21.4% |
| 5 years | -98.1% | +75.2% | −173.3 pts | -54.7% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases ImageneBio filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- Results
About ImageneBio
Biological Products, (No Diagnostic Substances)
ImageneBio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics for patients suffering from immunological, autoimmune, and inflammatory diseases. The company's lead product candidate is IMG-007, an investigational non-depleting anti-OX40 monoclonal antibody designed to selectively bind the OX40 receptor on activated T cells to block interactions with the OX40 ligand. Through this mechanism, the candidate attenuates pathological T-cell signaling across multiple inflammatory pathways without depleting T cells. ImageneBio focuses its initial clinical development of IMG-007 on patients with atopic dermatitis, while exploring potential utility in additional conditions such as alopecia areata, asthma, rheumatoid arthritis, and hidradenitis suppurativa.
Company profile, executives and historyImageneBio stock: common questions
What is ImageneBio's stock price?
IMA closed at $3.72 on Nov 11, 2026, down 2.36% on the day. Over the past 52 weeks it traded between $3.60 and $8.84.
What is ImageneBio's market cap?
ImageneBio was worth $42.23M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is IMA's P/E ratio?
ImageneBio lost money over fiscal 2025 (diluted EPS -$9.64), so it has no meaningful P/E ratio.
How much revenue does ImageneBio make?
ImageneBio reported revenue of $800.00K for fiscal 2025, down 77.1% from a year earlier.
Does ImageneBio pay a dividend?
No. ImageneBio has not paid a cash dividend over the last twelve months.
When does ImageneBio report earnings next?
ImageneBio is expected to report Q4 FY2026 results on Mar 9, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has IMA stock performed over the past year?
Including dividends, IMA returned -56.8% over the past year, against +12.4% for the S&P 500.
How many IMA shares are sold short?
0M shares were sold short at the latest FINRA report, 0.86% of the float, or 4.0 days of average trading volume.
Who are ImageneBio's competitors?
Companies most similar to ImageneBio by business, industry and size include CMPX, ARTV, SABS, PALI, INBX.
See a number that looks wrong?